Celldex Therapeutics financials
$31.64+0.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M | $7.4M | $3.6M |
| Gross profit | $1.5M | $7.0M | $6.9M | $2.4M | $4.7M | $7.4M | $3.6M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$287.4M | -$195.1M | -$154.5M | -$115.2M | -$72.6M | -$67.6M | -$56.3M |
| Net income | -$258.8M | -$157.9M | -$141.4M | -$112.3M | -$70.5M | -$59.8M | -$50.9M |
| Net margin | −16748.0% | −2248.8% | −2054.8% | −4765.6% | −1516.0% | −805.9% | −1424.0% |
| Diluted EPS | $-3.90 | $-2.45 | $-2.92 | $-2.40 | $-1.64 | $-2.02 | $-3.51 |
| EBITDA | -$284.0M | -$191.9M | -$139.0M | -$104.2M | -$66.1M | -$45.6M | -$49.7M |
| Operating cash flow | -$210.9M | -$157.8M | -$107.3M | -$96.9M | -$59.5M | -$40.4M | -$46.4M |
| Free cash flow | -$213.7M | -$159.7M | -$109.1M | -$98.7M | -$60.8M | -$42.0M | -$47.1M |
| Diluted shares | 66.4M | 64.4M | 48.4M | 46.9M | 42.9M | 29.6M | 14.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.9M | $28.4M | $34.8M | $29.4M | $39.1M | $43.8M |
| Short-term investments | $489.7M | $696.9M | $388.8M | $275.5M | $369.1M | $150.6M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $583.0M | $792.3M | $465.6M | $352.7M | $444.7M | $235.8M |
| Total liabilities | $55.8M | $45.3M | $36.5M | $26.5M | $25.2M | $26.5M |
| Shareholders' equity | $527.2M | $747.0M | $429.2M | $326.2M | $419.5M | $209.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology